^
    Back
    Association details:
    Biomarker:BRAF V600E + PD-L1 expression
    Cancer:Thyroid Gland Anaplastic Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer

    Published date:
    10/22/2017
    Excerpt:
    We describe a 62‐year‐old male who was diagnosed with ATC...and the tumor was found to have BRAF and programmed death‐ligand 1 (PD‐L1) positivity that was subsequently treated with vemurafenib and nivolumab....Currently, the patient continues to be in complete radiographic and clinical remission 20 months after beginning treatment with nivolumab.
    DOI:
    10.1634/theoncologist.2017-0096